CTLA4 and cancer: Another study by Rojas et al. demonstrated that the combination of an oncolytic vaccinia virus with a CTLA4 inhibitor enhances anti-tumor response in mouse models of colon (MC38 cells) and renal (RENCA cells) cancer [67].